CN Patent

CN106102740A — 治疗先天性肾上腺增生的crf1受体拮抗剂

Assigned to Neurocrine Biosciences Inc · Expires 2016-11-09 · 10y expired

What this patent protects

CRF 1 受体拮抗剂可能直接抑制患有CAH的患者的ACTH释放，从而在使用多个较低生理剂量的氢化可的松时，使雄激素的产生正常化，并且因此减少治疗相关的副作用。

USPTO Abstract

CRF 1 受体拮抗剂可能直接抑制患有CAH的患者的ACTH释放，从而在使用多个较低生理剂量的氢化可的松时，使雄激素的产生正常化，并且因此减少治疗相关的副作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN106102740A
Jurisdiction
CN
Classification
—
Expires
2016-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.